NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00770120 2020-03-06
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT02352844 2018-10-02
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Washington University School of Medicine
Phase 2 Completed
NCT02449538 2017-02-17
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
Samsung Medical Center
Phase 2 Completed
NCT01024946 2015-05-12
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed